BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

698 related articles for article (PubMed ID: 24398308)

  • 21. A randomized phase 2 trial of apatinib vs observation as maintenance treatment following first-line induction chemotherapy in extensive- stage small cell lung cancer.
    Luo H; Zhang L; Yang B; Feng Y; Xiong Y; Zhang S; Li X; Qian C; Dong W; Dai N
    Invest New Drugs; 2020 Feb; 38(1):148-159. PubMed ID: 31399906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single-agent chemotherapy compared with combination chemotherapy as second-line treatment in extensive-stage small cell lung cancer: a retrospective analysis.
    Song Z; Shao L; Lin B; Zhang Y
    Clin Transl Oncol; 2013 Oct; 15(10):843-8. PubMed ID: 23423808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypo- or conventionally fractionated radiotherapy combined with chemotherapy in patients with limited stage small cell lung cancer.
    Zhang J; Fan M; Liu D; Zhao KL; Wu KL; Zhao WX; Zhu ZF; Fu XL
    Radiat Oncol; 2017 Mar; 12(1):51. PubMed ID: 28283034
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Multi-factor retrospective study in 91 small cell lung cancer patients].
    Liu Y; Zhu J; Liu X; Xin Y; Wang Y; Cheng Y
    Zhongguo Fei Ai Za Zhi; 2014 Aug; 17(8):588-95. PubMed ID: 25130964
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
    Lara PN; Moon J; Redman MW; Semrad TJ; Kelly K; Allen JW; Gitlitz BJ; Mack PC; Gandara DR
    J Thorac Oncol; 2015 Jan; 10(1):110-5. PubMed ID: 25490004
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of post-progression survival on overall survival among patients with sensitive relapse of small cell lung cancer.
    Miura Y; Imai H; Sakurai R; Kaira K; Sunaga N; Minato K; Saito R; Hisada T
    Med Oncol; 2018 Mar; 35(4):45. PubMed ID: 29508094
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High Systemic Immune-Inflammation Index (SII) Represents an Unfavorable Prognostic Factor for Small Cell Lung Cancer Treated with Etoposide and Platinum-Based Chemotherapy.
    Wang C; Jin S; Xu S; Cao S
    Lung; 2020 Apr; 198(2):405-414. PubMed ID: 32016563
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The predictive value of delta-like3 and serum NSE in evaluating chemotherapy response and prognosis in patients with advanced small cell lung carcinoma: An observational study.
    Zhu C; Huang J; Jin X; Zhang C; Zhu C; Lv M; Chen S; Du X; Feng G
    Medicine (Baltimore); 2024 Jun; 103(23):e38487. PubMed ID: 38847733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Paclitaxel as third-line chemotherapy for small cell lung cancer failing both etoposide- and camptothecin-based chemotherapy.
    Kim SH; Kim MJ; Kim YJ; Chang H; Kim JW; Lee JO; Lee KW; Kim JH; Bang SM; Lee JS
    Medicine (Baltimore); 2017 Oct; 96(42):e8176. PubMed ID: 29049199
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors associated with overall survival, progression-free survival and toxicity in patients with small cell lung cancer and thoracic irradiation in a clinical real-world setting.
    Kassik MT; Vordermark D; Kornhuber C; Medenwald D
    Radiat Oncol; 2023 Apr; 18(1):70. PubMed ID: 37072833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic factors in limited-stage small cell lung cancer of patients treated with combined modality approach.
    Cetingöz R; Cetinayak HO; Sen RC; Demiral AN; Akkoçlu A; Osma E; Kargi A; Oztop I; Onen A; Kinay M;
    J BUON; 2006; 11(1):31-7. PubMed ID: 17318949
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A randomized controlled study of chemotherapy: etoposide combined with oxaliplatin or cisplatin regimens in the treatment of extensive-stage small cell lung cancer in elderly patients].
    Pu D; Hou M; Li Z; Zeng X
    Zhongguo Fei Ai Za Zhi; 2013 Jan; 16(1):20-4. PubMed ID: 23327869
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment beyond four cycles of first line Platinum and Etoposide chemotherapy in real-life patients with stage IV Small Cell Lung Cancer: a retrospective study of the Merseyside and Cheshire Cancer network.
    Sallam M; Wong H; Escriu C
    BMC Pulm Med; 2019 Nov; 19(1):195. PubMed ID: 31675940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive and prognostic value of folate receptor-positive circulating tumor cells in small cell lung cancer patients treated with first-line chemotherapy.
    Shen J; Zhao J; Jiang T; Li X; Zhao C; Su C; Zhou C
    Oncotarget; 2017 Jul; 8(30):49044-49052. PubMed ID: 28467771
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic factors affecting the risk of thoracic progression in extensive-stage small cell lung cancer.
    Fukui T; Itabashi M; Ishihara M; Hiyoshi Y; Kasajima M; Igawa S; Sasaki J; Masuda N
    BMC Cancer; 2016 Mar; 16():197. PubMed ID: 26955807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Outcomes Following Stereotactic Body Radiation Therapy (SBRT) for Stage I Medically Inoperable Small Cell Lung Carcinoma: A Multi-Institutional Analysis From the RSSearch Patient Registry.
    Singh R; Ansinelli H; Sharma D; Jenkins J; Davis J; Vargo JA; Sharma S
    Am J Clin Oncol; 2019 Jul; 42(7):602-606. PubMed ID: 31232723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modified Glasgow Prognostic Score as a Prognostic Factor in Patients with Extensive Disease-Small-Cell Lung Cancer: A Retrospective Study in a Single Institute.
    Sonehara K; Tateishi K; Komatsu M; Yamamoto H; Hanaoka M; Kanda S; Koizumi T
    Chemotherapy; 2019; 64(3):129-137. PubMed ID: 31622969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Efficiency and adverse effects of the effective therapy applying etoposide + cisplatin and its subsequent maintenance therapy with different durations in patients with small cell lung cancer].
    Yang CL; Ma LX; Sun SY; Cui HX; Li ZL; Cheng Y
    Zhonghua Zhong Liu Za Zhi; 2016 Jun; 38(6):454-9. PubMed ID: 27346404
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508).
    Belani CP; Dahlberg SE; Rudin CM; Fleisher M; Chen HX; Takebe N; Velasco MR; Tester WJ; Sturtz K; Hann CL; Shanks JC; Monga M; Ramalingam SS; Schiller JH
    Cancer; 2016 Aug; 122(15):2371-8. PubMed ID: 27163943
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can consolidative thoracic radiotherapy improve outcomes in extensive-disease small cell lung cancer after chemotherapy with complete/near-complete responders?
    Kirakli EK; Yilmaz H; Akcay C; Komurcuoglu B; Yilmaz U
    J Cancer Res Ther; 2020; 16(4):752-756. PubMed ID: 32930114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.